EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieÄquivalenzstudieOpen Access

Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting

Winfried Alsdorf iD, Joris Diels iD, Francesca Ghilotti, João Mendes, Teresa Hernando, Patricia Cost, Jordan M Schecter, Nikoletta Lendvai, Nitin Patel, Ana Triguero iD, Margherita Ursi iD

Journal of Comparative Effectiveness Research · 2024

DOI: 10.57264/cer-2024-0080 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Comparative Effectiveness Research, 2024. Verfasst von Winfried Alsdorf und 10 weiteren Autor:innen. Beteiligte Einrichtung: University Medical Center Hamburg-Eppendorf, 20251, Hamburg, Germany. Hauptthemen laut MEDLINE: Multiple Myeloma, Lenalidomide, Dexamethasone, Thalidomide. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

The phase III randomized controlled trial (RCT) CARTITUDE-4 (NCT04181827) demonstrated superiority of CARVYKTI (ciltacabtagene autoleucel; cilta-cel) over daratumumab, pomalidomide and dexamethasone (DPd) and pomalidomide, bortezomib and dexamethasone (PVd) for relapsed/refractory multiple myeloma (RRMM) patients who have received one to three prior line(s) of therapy (LOT[s]) including an immunomodulatory agent and a proteasome inhibitor, and are refractory to lenalidomide. These analyses estimate the relative efficacy between cilta-cel and other common treatment regimens, for which no direct comparative evidence is available. Materials & methods: Patient data were available from the CARTITUDE-4, CASTOR, CANDOR and APOLLO RCTs. Imbalances between cohorts on key patient characteristics were adjusted for using inverse probability of treatment weighting (IPTW). Relative efficacies were estimated with response rate ratios (RRs) and 95% confidence intervals (CIs) for overall response rate (ORR), very good partial response or better rate (≥VGPR) and complete response or better rate (≥CR), and with hazard ratios (HRs) and 95% CIs for progression-free survival (PFS). Sensitivity analyses using different analytical methods and additional covariates were explored.

Results

Key characteristics were well balanced across cohorts after IPTW. Cilta-cel showed statistically significant benefit in PFS (HRs: 0.11–0.51), ≥VGPR (RRs: 1.51–5.13) and ≥CR (RRs: 2.90–35.24) versus all comparators, and statistically significant improvements in ORR over most comparator regimens (RRs: 1.22–1.90). Results were consistent across sensitivity analyses.

Conclusion

Cilta-cel demonstrated benefit over other common treatment regimens, highlighting its potential to become a new standard of care option for lenalidomide-refractory RRMM patients with one to three prior LOT(s). These comparisons help to demonstrate the improved efficacy of cilta-cel in countries where the standard of care may differ from DPd/PVd.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaLenalidomideDexamethasoneThalidomideHumansMaleFemaleMiddle AgedAgedAntineoplastic Combined Chemotherapy ProtocolsImmunotherapy, AdoptiveBortezomibTreatment OutcomeAntibodies, Monoclonal

Stichwörter der Autor:innen

CARTITUDE-4CARVYKTIciltacabtagene autoleucelindirect comparisonlenalidomide-refractoryrelapsed or refractory multiple myeloma

Substanzen

LenalidomideDexamethasoneThalidomideBortezomibpomalidomidedaratumumabAntibodies, Monoclonal

Autor:innen und Institutionen

  • University Medical Center Hamburg-Eppendorf, 20251, Hamburg, Germany.
  • Janssen Pharmaceutica NV, 2340 Beerse, Belgium.
  • Janssen-Cilag SpA, 20126, Milano, Italy.
  • Jan-Cilag Farmacêutica, 2740-262, Porto Salvo, Portugal.
  • Janssen-Cilag S.A., 28703, Madrid, Spain.
  • Janssen Global Services, LLC, Raritan, NJ 08869, USA.

ORCID-Profile: Winfried Alsdorf, Joris Diels, Ana Triguero, Margherita Ursi

Zitieren

APA

Alsdorf, W., Diels, J., Ghilotti, F., Mendes, J., Hernando, T., Cost, P., Schecter, J. M., Lendvai, N., Patel, N., Triguero, A., & Ursi, M. (2024). Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting. Journal of Comparative Effectiveness Research. https://doi.org/10.57264/cer-2024-0080

Vancouver

Alsdorf W, Diels J, Ghilotti F, Mendes J, Hernando T, Cost P, et al. Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting. Journal of Comparative Effectiveness Research. 2024. doi:10.57264/cer-2024-0080

BibTeX
@article{Alsdorf2024,
  author = {Alsdorf, Winfried and Diels, Joris and Ghilotti, Francesca and Mendes, João and Hernando, Teresa and Cost, Patricia and Schecter, Jordan M and Lendvai, Nikoletta and Patel, Nitin and Triguero, Ana and Ursi, Margherita},
  title = {Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting},
  journal = {Journal of Comparative Effectiveness Research},
  year = {2024},
  doi = {10.57264/cer-2024-0080}
}
Kostenlos starten →